Mendus
8,824 SEK -0,15%150 investorer følger denne virksomhed
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (adj.) (24e)
-3,17
EV/EBIT (adj.) (24e)
-2,76
P/B (24e)
0,69
Udbytteafkast, % (24e)
-
Kursmål
14.00 SEK
Anbefaling
Køb
Opdateret
26.8.2024
NASDAQ Stockholm
IMMU
Daglig lav / høj pris
8,5 / 8,92
SEK
Markedsværdi
444,37 mio. SEK
Aktieomsætning
343,33 t SEK
Volumen
40 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalytiker
Antti Siltanen
Analytiker
Seneste videoer
Finanskalender
Delårsrapport
08.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Adrianus Van Herk | 35,7 % | 35,7 % |
| Flerie Invest AB | 23,9 % | 23,9 % |
| Fourth Swedish National Pension Fund (AP4) | 9,9 % | 9,9 % |
| Avanza Pension | 2,8 % | 2,8 % |
| Holger Blomstrand Byggnads AB | 1,3 % | 1,3 % |
| Nordnet Pensionsförsäkring | 1,0 % | 1,0 % |
| SEB Funds | 0,7 % | 0,7 % |
| Erik Manting | 0,6 % | 0,6 % |
| Handelsbanken Fonder | 0,5 % | 0,5 % |
| Dharminder Chahal | 0,5 % | 0,5 % |
Resultatopgørelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| vækst-% | 150,0 % | -60,0 % | 150,0 % | |||||
| EBITDA | -86,9 | -132,0 | -138,5 | -133,2 | -139,1 | -140,4 | -101,6 | -104,0 |
| EBIT (adj.) | -86,0 | -130,1 | -133,7 | -125,9 | -139,1 | -140,4 | -101,6 | -104,0 |
| EBIT | -86,0 | -130,1 | -133,7 | -125,9 | -139,1 | -140,4 | -101,6 | -104,0 |
| Overskud før skat | -89,2 | -133,4 | -138,8 | -126,9 | -140,3 | -143,4 | -104,6 | -107,0 |
| Netto indkomst | -89,2 | -133,4 | -138,8 | -126,9 | -140,3 | -143,4 | -104,6 | -107,0 |
| EPS (adj.) | -10,74 | -13,38 | -13,92 | -3,04 | -2,79 | -2,85 | -2,08 | -2,13 |
| vækst-% | ||||||||
| Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Udbytte ratio |
Lønsomhed og afkast på kapital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -869.130,0 % | -3.298.775,0 % | -1.385.420,0 % | -1.332.210,0 % | -1.390.640,0 % | -1.403.670,0 % | -1.015.680,0 % | -1.040.150,0 % |
| EBIT-% (adj.) | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.390.640,0 % | -1.403.670,0 % | -1.015.680,0 % | -1.040.150,0 % |
| EBIT-% | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.390.640,0 % | -1.403.670,0 % | -1.015.680,0 % | -1.040.150,0 % |
| ROE | -27,2 % | -20,2 % | -23,7 % | -20,8 % | -20,9 % | -25,2 % | -23,5 % | -31,6 % |
| ROI | -25,3 % | -19,4 % | -22,3 % | -20,2 % | -20,4 % | -22,5 % | -17,2 % | -17,6 % |
Værdiansættelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Aktiekurs (SEK) | 6,82 | 3,95 | 2,22 | 0,52 | 8,82 | 8,82 | 8,82 | 8,82 |
| Aktier | 8,3 | 10,0 | 10,0 | 41,8 | 50,4 | 50,4 | 50,4 | 50,4 |
| Markedsværdi | 56,6 | 39,4 | 22,1 | 21,9 | 444,4 | 444,4 | 444,4 | 444,4 |
| Enterprise value | -87,8 | -115,9 | 9,5 | -98,9 | 383,7 | 527,1 | 631,6 | 738,7 |
| EV/S | - | - | 948,4 | - | 38.370,8 | 52.707,5 | 63.164,3 | 73.865,9 |
| EV/EBITDA | 1,0 | 0,9 | - | 0,7 | - | - | - | - |
| EV/EBIT (adj.) | 1,0 | 0,9 | - | 0,8 | - | - | - | - |
| EV/EBIT | 1,0 | 0,9 | - | 0,8 | - | - | - | - |
| P/E (adj.) | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
| P/B | 0,1 | 0,1 | 0,0 | 0,0 | 0,7 | 0,9 | 1,1 | 1,6 |
| P/S | 5.663,0 | 9.837,9 | 2.213,4 | 2.186,5 | 44.437,3 | 44.437,3 | 44.437,3 | 44.437,3 |
| Udbytteprocent | ||||||||
| Equity ratio | 90,7 % | 91,1 % | 82,9 % | 93,2 % | 90,0 % | 77,4 % | 61,1 % | 44,5 % |
| Gearing ratio | -21,8 % | -23,6 % | -2,5 % | -17,1 % | -9,5 % | 16,6 % | 47,7 % | 103,1 % |
Kvartalsdata
| Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24e | Q4/24e | 2024e | Q1/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | |||||
| EBITDA | -29,0 | -42,7 | -133,2 | -35,3 | -34,1 | -34,8 | -34,9 | -139,1 | -34,8 |
| EBIT | -25,9 | -42,7 | -125,9 | -35,3 | -34,1 | -34,8 | -34,9 | -139,1 | -34,8 |
| Overskud før skat | -52,2 | -41,2 | -126,9 | -35,6 | -34,4 | -35,1 | -35,2 | -140,3 | -34,8 |
| Netto indkomst | -52,2 | -41,2 | -126,9 | -35,6 | -34,4 | -35,1 | -35,2 | -140,3 | -34,8 |
ViserAlle indholdstyper
Mendus to participate in upcoming industry conferences in September
Mendus Q2'24: Ilixadencel to return to the clinical arena
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Redeye: Mendus Q2 2024 - Catalysts are coming closer, solid funding position
Mendus Q2´24: The CADENCE trial has started
Mendus, Audiocast with teleconference, Q2'24
Mendus AB Interim Report January – June 2024
Mendus Q2'24 earnings preview: Patient recruitment started for CADENCE trial
Invitation to second quarter financial report and business update
Mendus brings ilixadencel back into clinical development
Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas
Change in number of shares and votes in Mendus AB (publ)
Mendus: Vididencel-induced anti-tumor immune responses in ovarian cancer
ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel
Mendus presented data on immune responses following vididencel administration
Mendus data presented at EHA substantiate the potential of vididencel to induce functional, clinically relevant immune responses in AML
Mendus to participate in upcoming industry conferences
Reverse share split in Mendus AB (publ)
AML development on track
